Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : Institutional experiences
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
PubMed
31309266
DOI
10.1007/s00066-019-01491-0
PII: 10.1007/s00066-019-01491-0
Knihovny.cz E-zdroje
- Klíčová slova
- 3D brachytherapy, 3T MRI-guided brachytherapy, Cervical cancer, Late side effects, Uterovaginal brachytherapy,
- MeSH
- brachyterapie škodlivé účinky MeSH
- celková dávka radioterapie * MeSH
- colon sigmoideum účinky záření MeSH
- frakcionace dávky záření MeSH
- kombinovaná terapie MeSH
- kritické orgány účinky záření MeSH
- lidé MeSH
- magnetická rezonanční tomografie * MeSH
- močový měchýř účinky záření MeSH
- nádory děložního čípku patologie radioterapie MeSH
- následné studie MeSH
- radiační poranění etiologie MeSH
- radioterapie řízená obrazem škodlivé účinky MeSH
- rektum účinky záření MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: This article reports experiences with 3T magnetic resonance imaging(MRI)-guided brachytherapy (BT) for cervical cancer focusing on late side effects. METHODS: Between June 2012 and March 2017 a total of 257 uterovaginal BT administrations were performed in 61 consecutive patients with inoperable cervical cancer. All patients were treated with BT combined with external beam radiotherapy. RESULTS: The mean HR-CTV (high risk-clinical target volume) D90 was 87 ± 5.1 Gy equivalent dose corresponding to the conventional fractionation using 2 Gy per fraction (EQD2, range 70.7-97.9 Gy). The mean doses in OAR (organs at risk), namely rectum, sigmoid and bladder were D2 cm3rectum = 62.6 ± 6.9 Gy EQD2 (range 38.2-77.2 Gy), D2 cm3sigmoid = 66.2 ± 6.8 Gy EQD2 (43.2-78.6 Gy) and D2 cm3bladder = 75.1 ± 8.3 Gy EQD2 (58.2-92.6 Gy). There were no signs of late gastrointestinal (GI) toxicity in 49 patients, grade 3 toxicity was seen in 2 patients and grade 4 toxicity in 3 patients. There were no signs of late genitourinary (GU) toxicity in 41 patients, grade 3 toxicity was seen in 4 patients and no signs of grade 4 toxicity were seen. After the treatment, 60 patients (98.4%) achieved locoregional remission. In 54 patients (88.5%) the remission was complete, whereas in 6 patients (9.8%) remission was partial. CONCLUSION: The use of 3T MRI-guided BT leads to achievement of high rates of local control with limited late morbidity as demonstrated in this series of patients.
Zobrazit více v PubMed
Brachytherapy. 2012 Jan-Feb;11(1):47-52 PubMed
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):540-7 PubMed
Lancet. 2001 Sep 8;358(9284):781-6 PubMed
Radiother Oncol. 2006 Jan;78(1):67-77 PubMed
Int J Cancer. 2015 Mar 1;136(5):E359-86 PubMed
Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):56-63 PubMed
Radiother Oncol. 2007 May;83(2):148-55 PubMed
Radiother Oncol. 2016 Sep;120(3):447-454 PubMed
Klin Onkol. 2014;27(1):45-51 PubMed
Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):608-617 PubMed
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1051-6 PubMed
Brachytherapy. 2012 Jan-Feb;11(1):33-46 PubMed
Radiother Oncol. 2011 Jul;100(1):116-23 PubMed
Insights Imaging. 2017 Oct;8(5):471-481 PubMed
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):588-97 PubMed
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):320-8 PubMed
J Clin Oncol. 2002 Feb 15;20(4):966-72 PubMed
Radiother Oncol. 2013 Apr;107(1):69-74 PubMed
Ceska Gynekol. 2008 Jun;73(3):144-9 PubMed
Jpn J Clin Oncol. 2012 Apr;42(4):309-13 PubMed
Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):871-8 PubMed
Radiother Oncol. 2006 Apr;79(1):80-6 PubMed
Radiother Oncol. 2005 Mar;74(3):235-45 PubMed
Strahlenther Onkol. 2016 Dec;192(12):922-930 PubMed
N Engl J Med. 1999 Apr 15;340(15):1137-43 PubMed
Acta Oncol. 2013 Oct;52(7):1510-9 PubMed
Strahlenther Onkol. 2019 May;195(5):430-440 PubMed
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):197-204 PubMed
Strahlenther Onkol. 2017 Jul;193(7):543-551 PubMed
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):619-27 PubMed
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88 PubMed
Radiother Oncol. 2003 Jul;68(1):51-9 PubMed
Int J Surg Oncol. 2018 Aug 1;2018:9120753 PubMed
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):491-8 PubMed
Radiother Oncol. 2003 Apr;67(1):69-76 PubMed
Radiother Oncol. 1992 Dec;25(4):273-9 PubMed
Oncologist. 2013;18(4):415-22 PubMed